Chromocell Therapeutics Corp Files 8-K

TL;DR

Chromocell Therapeutics filed an 8-K on Oct 22, 2024, covering shareholder votes, other events, and financials.

AI Summary

On October 22, 2024, Chromocell Therapeutics Corporation filed an 8-K report detailing a submission of matters to a vote of security holders, other events, and financial statements/exhibits. The company, incorporated in Delaware, is involved in biological products and is located at 685 US Highway One, North Brunswick, NJ.

Why It Matters

This filing indicates significant corporate actions and disclosures by Chromocell Therapeutics, which could impact investors and stakeholders.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of corporate events and does not appear to contain immediate negative news.

Key Numbers

• 001-41964 — Commission File Number (Identifies the company's filing with the SEC.)
• 86-3335449 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• Chromocell Therapeutics Corporation (company) — Registrant
• October 22, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 685 US Highway One, North Brunswick, NJ (address) — Registrant's principal executive office
• 001-41964 (company_id) — Commission File Number
• 86-3335449 (tax_id) — IRS Employer Identification No.

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share CHRO The NYSE American LL
• $500,000 — er the Repurchase Plan by an additional $500,000, to $750,000. In addition, the Amendmen
• $750,000 — hase Plan by an additional $500,000, to $750,000. In addition, the Amendment extends the

Filing Documents

• g084503_8k.htm (8-K) — 56KB
• g084503_ex99-1.htm (EX-99.1) — 11KB
• 0001753926-24-001759.txt ( ) — 244KB
• chro-20241022.xsd (EX-101.SCH) — 3KB
• chro-20241022_lab.xml (EX-101.LAB) — 33KB
• chro-20241022_pre.xml (EX-101.PRE) — 22KB
• g084503_8k_htm.xml (XML) — 4KB

01

Item 8.01 Other Events. On October 22, 2024, the board of directors of the Company authorized an amendment (the "Amendment") to the Company's existing stock repurchase plan, dated August 5, 2024 (as amended, the "Repurchase Plan") to increase the total value of shares of Common Stock available for repurchase by the Company under the Repurchase Plan by an additional $500,000, to $750,000. In addition, the Amendment extends the termination date of the Repurchase Plan from December 31, 2024 to June 30, 2025, prior to which Common Stock may be repurchased, unless completed sooner or otherwise extended. Open market purchases are intended to be conducted in accordance with applicable Securities and Exchange Commission regulations, including the guidelines and conditions of Rule 10b-18 and Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The timing and actual number of shares repurchased will depend on a variety of factors including trading price, the Company's financial performance, corporate and regulatory requirements and other market conditions. A copy of the press release dated October 24, 2024 announcing the Repurchase Plan Amendment is filed as Exhibit 99.1, and incorporated by reference herein.

01

Item 9.01

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 99.1 Press Release dated October 24, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 3

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 24, 2024 Chromocell Therapeutics Corporation By: /s/ Francis Knuettel II Name: Francis Knuettel II Title: Chief Executive Officer and Chief Financial Officer